Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2026
Event: Regulation FD Disclosure regarding results from a recent Type C meeting with the U.S. Food and Drug Administration (FDA). The full details are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the disclosure of the FDA Type C meeting results.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release on June 23, 2026, announcing the results of its FDA Type C meeting.
- Forward-Looking Statements: The filing contains forward-looking statements based on current expectations. These are not guarantees of future performance.
- Risks: Actual events or results may differ materially from those in the forward-looking statements. Limitations are detailed in Exhibit 99.1 and other SEC reports.
- Legal Status: Information furnished under Item 7.01 is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 23, 2026) for specific details on the FDA Type C meeting outcomes.
- Verify the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not provide financial data.
- Assess the impact of the FDA meeting results on the Company's development timeline and potential regulatory milestones.
- Monitor subsequent filings for any updates on the FDA's feedback or required actions.